Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

It was no coincidence that semaglutide produced such significant weight loss. Novo Nordisk had been actively searching ... as ...

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

To attract and retain workers, employers will focus on competitive salaries and flexible benefits, experts say.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

From GLP-1s to brand product innovation, the trend intelligence report details the overall surge of innovation and investment in women’s health technologies at the 2025 CES on Monday.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).